Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 6/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17186358 | 0.98 | PNP (0.56) | PNPALDH1A1GDAGRIA1GRIA2 | |
| Hydrochloric Acid SCHEMBL17186227 | 0.98 | PNP (0.56) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL8591405 | 0.83 | GDA (0.52) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL10629409 | 0.83 | PNP (0.62) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL27501471 | 0.82 | PNP (0.49) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL2435286 | 0.81 | GDA (0.57) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL9275484 | 0.81 | PNP (0.48) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL1898182 | 0.80 | PNP (0.62) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL27504062 | 0.80 | PNP (0.54) | PNPALDH1A1GDAGRIA1GRIA2 | |
| SCHEMBL9059986 | 0.79 | XDH (0.55) | PNPALDH1A1GDAGRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| WO-2023126758-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2023-07-06 | — | — | WO | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-20220282275-A1 | G-TO-T BASE EDITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-09-08 | — | — | US | claimed |
| WO-2020102659-A1 | G-TO-T BASE EDITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2020-05-22 | — | — | WO | claimed |
| US-9828633-B1 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-11-28 | — | — | US | claimed |
| EP-3074042-A1 | COMPOSITIONS | Globalacorn Ltd. (GB) | 2016-10-05 | — | — | EP | claimed |
| US-9206216-B2 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2015-12-08 | — | — | US | claimed |
| WO-2015079241-A1 | COMPOSITIONS | GLOBALACORN LTD (GB) | 2015-06-04 | — | — | WO | claimed |
| US-20150119352-A1 | DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN | GlobalAcornLtd. (GB) | 2015-04-30 | — | — | US | claimed |
| EP-2669291-A1 | Modified Nucleotides Methods and Kits | Pierce Biotechnology, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| US-8536323-B2 | Modified nucleotides | PIERCE BIOTECHNOLOGY, INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2012-10-04 | — | — | US | claimed |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | PIERCE BIOTECHNOLOGY, INC. (US) | 2011-10-27 | — | — | US | claimed |
| WO-2008033432-A2 | IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| CN-1973821-A | Medicine composition containing both anticancer medicine and its synergist | SHANDONG LANJIN BIOENGINEERING (CN) | 2007-06-06 | — | — | CN | claimed |
| EP-1525224-A1 | HYALURONIC ACID DERIVATIVES | Jasper Ltd. Liability Co. (US) | 2005-04-27 | — | — | EP | claimed |
| WO-2004013182-A1 | HYALURONIC ACID DERIVATIVES | JASPER LTD LIABILITY CO. (US) | 2004-02-12 | — | — | WO | claimed |
| US-20040009602-A1 | DNA modifying molecules and methods of use thereof | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119352-A1 | DINUCELOSIDE POLYPHOSPHATES FOR THE TREATMENT OF PAIN | P2RX3, P2RX2, P2RY10 | PNP 330/4885ALDH1A1 4482/4885GDA 1781/4885 |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | RNGTT, NUDT1, ADAR | PNP 15/4885ALDH1A1 2292/4885GDA 79/4885 |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | NUDT1, RNMT, RNGTT | PNP 21/4885ALDH1A1 2422/4885GDA 109/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | PNP 241/4885ALDH1A1 822/4885GDA 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.